Loading
Liver Disease Diagnosis and Treatment · Journal article
Viruses · August 14, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort of 655 people with HIV and metabolic dysfunction-associated steatotic liver disease demonstrates that weight gain is independently associated with a clinically meaningful increase in the FIB-4 fibrosis index over short-term follow-up. The association is independent of HIV and antiretroviral therapy variables, and weight change correlates with concurrent metabolic dysregulation. However, the study is limited to a surrogate marker of fibrosis progression rather than validated clinical endpoints, and generalizability beyond the studied cohort is uncertain.
Retrospective cohort study. People with HIV with ultrasound-defined metabolic dysfunction-associated steatotic liver disease who underwent routine clinical and laboratory assessments.. Intervention: Weight gain (exposure variable, not an intervention). n = 655.
59 of 655 participants (9.0%) met prespecified FIB-4 increase definition over median 12.0 months, corresponding to 8.8 events per 100 person-years Weight gain was associated with FIB-4 increase: adjusted hazard ratio 1.19 per 1% increase (95% CI 1.14–1.24) Transition from non-obesity to obesity associated with outcome: odds ratio 8.45 (95% CI 3.57–20.02)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This finding suggests that weight management may be a modifiable target to slow short-term FIB-4 progression in people with HIV and MASLD. However, clinicians should recognize that FIB-4 is a non-invasive fibrosis index and that FIB-4 increase does not directly establish progression of liver fibrosis or predict clinical outcomes; further validation linking these FIB-4 changes to hard liver endpoints is needed before recommending weight loss as a primary intervention.
Retrospective cohort study with clear outcome definition and statistically significant associations between weight gain and FIB-4 increase in a defined population, but limited by observational design and surrogate endpoint (FIB-4 rather than fibrosis progression or clinical liver outcomes).
As stated by the source record.
Quoted from the source exactly as published.
This finding suggests that weight management may be a modifiable target to slow short-term FIB-4 progression in people with HIV and MASLD. However, clinicians should recognize that FIB-4 is a non-invasive fibrosis index and that FIB-4 increase does not directly establish progression of liver fibrosis or predict clinical outcomes; further validation linking these FIB-4 changes to hard liver endpoints is needed before recommending weight loss as a primary intervention.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Short-term variation in the Fibrosis-4 index (FIB-4) may identify people who warrant further liver assessment. We evaluated longitudinal FIB-4 changes and associated metabolic factors in people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: This retrospective cohort included 683 PWH with ultrasound-defined MASLD who underwent routine clinical and laboratory assessments approximately every three months. A prespecified FIB-4 increase required both a ≥20% rise and crossing to ≥1.3 among participants with baseline FIB-4 < 1.3, or a ≥20% rise among those with baseline FIB-4 ≥ 1.3. Results: Of 683 enrolled participants, 655 were analyzed longitudinally. Over a median follow-up of 12.0 months, 59 (9.0%) met the FIB-4 increase definition, corresponding to 8.8 events per 100 person-years. Weight gain was associated with this outcome (adjusted hazard ratio 1.19 per 1% increase, 95% CI 1.14–1.24), whereas HIV- and antiretroviral therapy-related variables were not. Transition from non-obesity to obesity was associated with the outcome (odds ratio 8.45, 95% CI 3.57–20.02). Weight change also correlated with concurrent changes in total cholesterol, triglycerides, fasting glucose, and liver enzymes (all p < 0.01). Conclusions: Weight gain was associated with short-term FIB-4 increase and with concurrent metabolic change in PWH with MASLD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.